Insulin-like growth factor I, IGF binding protein 3, and IGFBP protease activity: relation to anthropometric indices in solid tumours or leukaemia

B M D Brennan, M Gill, L Pennells, O B Eden, A G Thomas, P E Clayton

Abstract

Objectives—To measure the serum concentrations of insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3), and the level of IGFBP-3 protease activity in 38 children presenting with malignancies, and to assess their relation with auxological parameters and nutritional status.

Methods—Height, weight, skinfold thickness, and mid-upper arm circumference (MUAC) were recorded using standard techniques. IGF-I and IGFBP-3 were measured using specific radioimmunoassays. Serum IGFBPs were also visualised on western ligand blot. IGFBP-3 protease activity was assessed by the extent of fragmentation of recombinant [125I]-IGFBP-3, compared with that induced by pregnancy serum. Anthropometric and radioimmunoassay data were expressed as standard deviation scores (SDS).

Results—The median (range) IGF-I SDS was significantly reduced in all patients (−1.1 (−5.1 to 1.2)) and lower in children who were malnourished (−2.5 (−3.9 to 0.1)). IGFBP-3 SDS was within the normal range for 31 of 38 patients but IGFBP-3 protease activity was raised in all patients. Neither IGFBP-3 concentration nor protease activity was affected by nutritional status. IGF-I correlated with MUAC (r = 0.41) and subscapular skinfold thickness SDS (r = 0.38), but not with weight, height, weight for height, or triceps skinfold thickness.

Conclusions—IGF-I is low in children with malignancies, and even lower in those who are malnourished. IGFBP-3 concentrations were normal in most patients but interpretation is complicated by the presence of raised IGFBP-3 protease activity, which could lead to overestimating concentrations of intact peptide. IGF-I appears to relate to arm anthropometry as an index of nutritional status but not height, weight, or weight for height, as would be expected in normal children.

Patients and methods

PATIENTS
Thirty eight children (median age, 4.7 years; range, 0.5–15.8) with either solid malignant tumours (n = 26) or acute leukaemia (n = 12) were studied at presentation, before the initiation of treatment, which included surgery, chemotherapy, or radiotherapy. Table 1 gives the exact diagnoses. Subjects were enrolled in our study after informed consent was obtained from their parents. The presence of any other condition associated with failure to thrive or poor growth led to exclusion. Our study had the approval of the local ethics committee.

SERUM SAMPLES
We obtained blood samples from the children after an overnight fast, at a time when venepuncture was carried out for clinical reasons. Blood was then centrifuged and the
serum separated and stored at −70°C until analysis.

ANTHROPOMETRY
We performed anthropometric assessments in all patients. Height (or supine length), weight, mid-upper arm circumference (MUAC), triceps skinfold thickness (TSFT), and subscapular skinfold thickness (SSFT) were all measured by one observer (BMDB) using standard techniques.12–14 Weight was expressed as weight for height, in accordance with the recommendations of the WHO.15 We considered a child to be malnourished if any one of the following criteria was fulfilled: (1) a weight for height of less than 85%; (2) MUAC less than the fifth centile;16 (3) any skinfold thickness less than the third centile.14

IGF-I RADIOMUNOASSAY
We determined the serum IGF-I concentration by radioimmunoassay (RIA) (Nichols Institute Diagnostics, San Juan Capistrano, California, USA), following acid/ethanol extraction of its binding proteins. Assay sensitivity was 8.4 µg/l. The interassay coefficient of variation (CV) was 5.2–8.4% and the intra-assay CV was 2.4–3%. The interassay coefficient of variation (CV) was 5.3–6.3% and the intra-assay CV was 3.4–8%. Age and sex matched normal ranges (mean (2 SD)) for IGF-1 and IGFBP-3 were provided by the Nichols Institute.

WESTERN LIGAND BLOT ANALYSIS OF IGFBP-3
We carried out western ligand blot analysis of IGFBP's, as described originally by Hossenlope et al,16 on 36 serum samples. Briefly, 5 µl samples were diluted 1/10 in loading buffer (0.125 M Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, and 0.25% bromophenol blue) and then electrophoresed through a non-reducing SDS polyacrylamide gel (3% stacking gel/15% separating gel). The gel was dried, exposed to x ray film, and proteolysed [125I]-IGFBP-3 bands were quantitated by densitometry. As controls for the assay, the following samples were run on each gel: (1) [125I]-IGFBP-3 in assay buffer; (2) [125I]-IGFBP-3 in assay buffer, incubated overnight; (3) pooled pregnancy serum and [125I]-IGFBP-3; and (4) pooled pregnancy serum, [125I]-IGFBP-3, and a protease inhibitor (10 mM phenylmethylsulphonylfluoride (PMSF)). The proteolytic activity in each serum sample was expressed as a percentage of that found in the pooled pregnancy serum. According to previous studies,16 18 proteolytic activity exceeding 30% of that found in pregnancy serum was considered to be raised.

ASSOCIATION BETWEEN ANTHROPOMETRIC AND WEIGHT AND HEIGHT-RELATED INDICES

Comparison between the groups was made by the Mann-Whitney U test, and relations between variables by Spearman correlation.

Results
The median (range) SD scores for weight, height, and weight for height were −0.31 (−3.6 to 2.8), −0.1 (−1.8 to 3.6), and −0.1 (−2.8 to 2.7), respectively, which were not significantly different from normal. In contrast, the median SD scores (range) for MUAC, TSFT, and SSFT were −1.0 (−5.1 to 1.2), −0.8 (−4.1 to 3.1), and −1.0 (−3.4 to 2.5), respectively, which were significantly different from normal (all p < 0.01). This dichotomy between arm anthropometry and weight and height related indices held for the subgroup of solid tumours but not for those patients with acute leukaemia (table 2). Only one child with acute leukaemia was malnourished but 13 of the 26 children with solid tumours fulfilled the definition of malnutrition. All patients satisfied the

Table 1 Diagnosis of children with malignancies

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute leukaemia</td>
<td>12</td>
</tr>
<tr>
<td>Renal tumour</td>
<td>7</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>5</td>
</tr>
<tr>
<td>Hodgkin’s disease</td>
<td>3</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Germ cell tumour</td>
<td>2</td>
</tr>
<tr>
<td>Liver tumour</td>
<td>2</td>
</tr>
<tr>
<td>B-cell non-Hodgkin’s lymphoma</td>
<td>2</td>
</tr>
<tr>
<td>Nasopharyngeal carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Bone tumour</td>
<td>2</td>
</tr>
</tbody>
</table>
Table 2 Median (range) anthropometric standard deviation scores in patients with solid tumours and acute leukaemia

<table>
<thead>
<tr>
<th></th>
<th>Solid tumours</th>
<th>Leukaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height</td>
<td>−0.2 (−1.9 to 1.3)</td>
<td>−0.04 (−0.7 to 3.6)</td>
</tr>
<tr>
<td>Weight</td>
<td>−0.4 (−3.6 to 1.9)</td>
<td>−0.3 (−1.2 to 2.8)</td>
</tr>
<tr>
<td>Weight/height</td>
<td>0.1 (−2.8 to 1.9)</td>
<td>−0.2 (−1.6 to 2.7)</td>
</tr>
<tr>
<td>MUAC</td>
<td>−1.3 (−3.9 to 1.8)*</td>
<td>−0.7 (−1.3 to 2.5)</td>
</tr>
<tr>
<td>TSFT</td>
<td>−0.9 (−4.1 to 2.7)*</td>
<td>−0.5 (−1.5 to 3.2)</td>
</tr>
<tr>
<td>SSFT</td>
<td>−1.4 (−3.4 to 2.3)*</td>
<td>0.6 (−1.5 to 3.2)</td>
</tr>
</tbody>
</table>

*p < 0.01.

Figure 2 ¹²⁵I-IGFBP-3 protease assay on sera from patients (lanes 1–9); pooled pregnancy serum and 10 mM protease inhibitor phenylmethylsulphonylfluoride (lane 10); pooled pregnancy serum (lane 11); pooled male serum (lane 12); ¹²⁵I-IGFBP-3 only (lane 13); ¹²⁵I-IGFBP-3 incubated overnight at 37°C (lane 14). Molecular size markers are indicated on the left, and the bracket on the right indicates the proteolysed ¹²⁵I-IGFBP-3 fragments measured by densitometry.

Figure 1 IGF-I SD scores in malnourished (n = 14) and nourished (n = 24) tumour patients. Horizontal bars represent the median values.

definition of malnutrition based on arm anthropometry. However, all but four of these malnourished patients had normal weight related indices as a result of the assumed tumour mass contributing to the weight.

The median (range) IGF-I SD scores were significantly different from normal in the whole group (−1.1 (−5.1 to 1.2); p < 0.01), in the solid tumour group (−1.4 (−3.9 to 1.2); p < 0.01), and in the acute leukaemia group (−0.9 (−5.1 to 0.7); p < 0.01). The median (range) SD score of IGF-I of the 14 malnourished children was −2.5 (−3.9 to 0.1), which was significantly lower than that of the 24 nourished children, (−0.8 (−5.1 to 1.2); p = 0.03) (fig 1). However, there was considerable overlap in the IGF-I values between the two groups. The significant difference in IGF-I SD scores between nourished and malnourished children remained in the solid tumour subgroup, where the median (range) IGF-I SD scores for the malnourished (n = 13) and nourished (n = 13) children were −2.4 (−3.9 to 0.1) and 0.7 (−2.9 to 1.2), respectively (p = 0.02).

In contrast to the IGF-I SD score, the median (range) IGFBP-3 SD scores were not significantly different from normal in either the whole group (0.2 (−10.2 to 1.5); p = 0.7), the subgroups of acute leukaemia (1.0 (−3.1 to 1.7); p = 0.6), or solid tumours (0.1 (−10.2 to 1.5); p = 0.8). IGF-I was significantly correlated with IGFBP-3 for the whole group (r = 0.7; p < 0.001).

Serum concentrations of IGFBP-3 were within 2 SD of the mean in 31 subjects but IGFBP-3 was only detected by western ligand blot in 16 of 36 patients. There was no correlation between IGFBP-3 detected on western ligand blot and IGFBP-3 measured by RIA in the whole group (r = 0.3; p = 0.2). IGFBP-3 proteolysis was present in serum from all patients with the appearance of a 15–23 kDa band (fig 2). The median (range) protease activity of the whole group was 138% (43–213%) of pooled pregnancy serum. There was no significant difference in protease activity between malnourished and nourished subjects, median (range) protease activity was 127% (72–213%) and 140% (43–195%), respectively. In addition, there was no significant difference in protease activity between those with solid tumours and those with leukaemia.

Again, in contrast to the IGF-I SD score, the IGFBP-3 SD score was not significantly different between the malnourished and nourished children: median (range) IGFBP-3 SD scores for malnourished and nourished groups were −0.2 (−10.2 to 1.5) and 0.4 (−4.2 to 1.4), respectively. There were no differences in IGFBP-3 SD scores between the nourished and malnourished solid tumour patients.

Both MUAC and SSFT SD scores correlated positively with IGF-I SD scores (r = 0.41, p = 0.02; r = 0.38, p = 0.03, respectively), but not with IGFBP-3 SD scores (r = 0.3, p = 0.06; r = 0.3, p = 0.08, respectively). There was no correlation between weight, height, weight for height, and TSFT SD scores and either IGF-I or IGFBP-3 SD scores.

Discussion

We have shown that the serum IGF-I SD score is significantly reduced in children with malignancies at presentation, and even lower in those who are also malnourished. Furthermore, IGF-I relates to arm anthropometry as an index of nutritional status but not to height, weight, or weight for height, as would be expected in normal children.

In children with Wilms’ tumour, serum IGF-I concentrations have been reported to be different from a control group. However, nutritional status in these patients was not stated. In contrast, Mohnike et al assessed serum IGF-I concentrations in 15 children
with acute leukaemia at presentation and found that the mean IGF-I SD score was reduced to $\approx 3.0$. The SD score returned to normal during chemotherapy, despite severe nutritional problems.

Low IGF-I concentrations have been found in children with protein energy malnutrition. Soliman et al reported low serum IGF-I concentrations in 51 children with malnutrition, which increased after nutritional rehabilitation. IGF-I was a more sensitive index of nutritional status than serum albumin, correlating both with the expected weight for age and cross sectional arm fat.

Short term dietary restriction also affects IGF-I concentrations in normal children. A calorie reduction of 50% caused a significant decline in IGF-I concentrations within six days in eight normal children. Protein restriction had a similar effect. In our study, serum IGF-I concentrations were low for the whole group, despite the fact that only half the subjects were malnourished. However, IGF-I concentrations were lower in the malnourished subgroup. It is likely that in all our children the energy and protein intake would be reduced before tumour diagnosis, with the malnourished subjects suffering the more intense and prolonged nutrient restriction and hence showing a greater reduction in IGF-I concentrations.

Acute dietary changes do not affect IGFBP-3, its concentration remaining stable during the day and being unaffected by meals. However, in states of prolonged severe malnutrition, such as anorexia nervosa, IGFBP-3 is significantly decreased, together with IGF-I. In addition, calorie restriction to 50% of normal intake significantly decreased IGFBP-3 in children but not in adults, while protein restriction had no effect on IGFBP-3 in children, but caused a modest decrease in adults.

Serum concentrations of IGFBP-3 as measured by RIA were not significantly reduced in our patients and did not correlate with IGFBP-3 measured by western ligand blot. In fact, IGFBP-3 was not detected by western ligand blot in half of the subjects. This suggested that IGFBP-3 protease activity could be increased, and this was confirmed by the protease assay. These findings agree with those of Muller et al, who found normal IGFBP-3 concentrations and raised IGFBP-3 protease activity in 34 children with solid tumours and leukaemia. This discrepancy results from the ability of the RIA to recognise IGFBP-3 fragments produced by proteases, generating falsely normal or even high concentrations of serum IGFBP-3. The lower affinity of the IGFBP-3 fragments for IGF-I will also tend to raise the bioavailability of IGF-I. The net effect on IGF-I action will thus depend on the opposing influences of reduction in IGF-I concentrations and a rise in IGFBP-3 protease activity.

Oster et al predicted that IGFBP-3 proteases would be more active in severe protein and/or calorie malnutrition. However, their experiments in protein and calorie restriction of young adult rats failed to show an increase in IGFBP-3 specific protease activity, despite a fall in IGF-I and IGFBP-3 concentrations. IGFBP-3 protease activity was increased in all our patients, malnourished and nourished, implying that the malignancy rather than the nutritional status was the trigger to increased protease activity.

In our study, IGF-I concentrations correlated with arm anthropology and skinfold thickness but not with height, weight, or weight for height. Our findings might be explained by the poor reliability of weight related indices in the assessment of nutritional status in children with malignancies. Because arm anthropology is independent of tumour mass, and hence probably a better indicator of nutritional status, our findings of a positive correlation between MUAC or SSFT and IGF-I SD scores support those of Smith et al.

In animal models, serum IGF-I concentrations are significantly reduced in dietary restricted rats, concomitant with a decrease in cancer incidence. In fact, correction of the lowered IGF-I by exogenous IGF-I in diet restricted, heterozygous p53 deficient mice, induced to develop a preneoplastic bladder lesion with p-cresidine, increased cancer stage and decreased apoptosis. Therefore, it is possible that the low IGF-I concentrations found in our study are important in limiting tumour progression.

IGF-I is low at presentation in children with malignancies and even lower in those who are malnourished. There is, however, considerable overlap between IGF-I concentrations in nourished and malnourished groups, indicating that it is not a reliable test of nutritional status. Serum IGFBP-3 is normal in children with malignancies, and has no relation to nutritional status. Its interpretation is complicated by the presence of raised IGFBP-3 protease activity. The disruption of the normal relation between IGF-I and IGFBP-3 appears to result from a number of factors, including the presence of the tumour itself and nutritional status. Strategies to maintain the relatively low IGF-I bioavailability, could be important in limiting tumour progression.

21 Mohnike K, Blum WF, Mitiller U, Kluba U, Ranke MB. IGF-I, IGF-II, IGFBP-3 serum levels are supressed in acute lymphoblastic leukaemia (ALL) and increase during therapy [abstract]. Horm Res 1992;37:55.
Insulin-like growth factor I, IGF binding protein 3, and IGFBP protease activity: relation to anthropometric indices in solid tumours or leukaemia

B M D Brennan, M Gill, L Pennells, O B Eden, A G Thomas and P E Clayton

Arch Dis Child 1999 80: 226-230
doi: 10.1136/adc.80.3.226

Updated information and services can be found at:
http://adc.bmj.com/content/80/3/226

These include:

References
This article cites 22 articles, 5 of which you can access for free at:
http://adc.bmj.com/content/80/3/226#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: CNS (not psychiatric) (497)
- Drugs: endocrine system (120)
- Immunology (including allergy) (2018)
- Oncology (777)
- Pregnancy (528)
- Reproductive medicine (945)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/